Esperion Therapeutics (NASDAQ:ESPR) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Esperion Therapeutics (NASDAQ:ESPR) posted its earnings results on Tuesday. The biopharmaceutical company reported $0.22 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.01), FiscalAI reports. The business had revenue of $168.45 million for the quarter, compared to analyst estimates of $165.12 million.

Here are the key takeaways from Esperion Therapeutics’ conference call:

• Esperion agreed to acquire Corstasis, giving it global rights to Enbumyst (an FDA‑approved intranasal diuretic) with the deal expected to close in Q2 2026 and immediate cross‑selling opportunities into its existing cardiology sales footprint.
• Commercial momentum continued: Q4 sales grew 38% in the U.S., retail prescription equivalents rose 34%, prescribers increased ~25%, and the company expects favorable positioning in imminent U.S. dyslipidemia guidelines plus recognition for hsCRP reduction benefits.
• Financials strengthened (record 2025 revenue, $167.9M cash, $55M debt repayment), but Q4 collaboration revenue included a one‑time $90M Otsuka payment and 2026 partnership/manufacturing transfers create moving parts that could alter partner revenue timing and mix.
• Pipeline progress includes nomination of ESP‑2001 for primary sclerosing cholangitis with IND‑enabling work underway (clinic by year‑end) and two triple‑combination programs targeted for clinical/regulatory completion toward 2027 commercialization (potential ~70% LDL reductions).

Esperion Therapeutics Stock Performance

ESPR stock traded up $0.02 during mid-day trading on Wednesday, reaching $2.72. 1,860,890 shares of the stock traded hands, compared to its average volume of 4,810,090. Esperion Therapeutics has a one year low of $0.69 and a one year high of $4.18. The stock has a market capitalization of $649.05 million, a PE ratio of -5.41, a PEG ratio of 0.62 and a beta of 1.11. The business has a 50-day moving average price of $3.35 and a two-hundred day moving average price of $3.14.

Insider Buying and Selling

In related news, CFO Benjamin Halladay sold 7,337 shares of the stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $3.67, for a total value of $26,926.79. Following the sale, the chief financial officer directly owned 467,525 shares of the company’s stock, valued at $1,715,816.75. This represents a 1.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last 90 days, insiders have sold 15,543 shares of company stock worth $55,709. Corporate insiders own 1.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ESPR. Sivia Capital Partners LLC purchased a new position in shares of Esperion Therapeutics during the second quarter worth approximately $25,000. Kestra Advisory Services LLC purchased a new position in Esperion Therapeutics in the 4th quarter worth approximately $35,000. Captrust Financial Advisors acquired a new position in shares of Esperion Therapeutics in the 4th quarter worth approximately $40,000. CIBC Bancorp USA Inc. purchased a new position in shares of Esperion Therapeutics in the third quarter valued at approximately $56,000. Finally, Cibc World Markets Corp purchased a new position in Esperion Therapeutics in the fourth quarter worth approximately $57,000. 47.39% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ESPR shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Esperion Therapeutics in a research report on Wednesday, November 12th. Piper Sandler started coverage on shares of Esperion Therapeutics in a report on Tuesday, November 25th. They issued an “overweight” rating and a $9.00 target price for the company. Citigroup reiterated a “market outperform” rating on shares of Esperion Therapeutics in a research report on Wednesday, November 12th. HC Wainwright reiterated a “buy” rating on shares of Esperion Therapeutics in a research note on Tuesday. Finally, Needham & Company LLC increased their target price on Esperion Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $8.25.

Key Headlines Impacting Esperion Therapeutics

Here are the key news stories impacting Esperion Therapeutics this week:

• Positive Sentiment: Strong top-line results: Esperion reported Q4 revenue of $168.45M and FY25 revenue of $403.1M (21% Y/Y); U.S. net product revenue rose 38% Y/Y to $159.6M — results investors see as validation of commercial momentum. Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Company announced an acquisition alongside the quarter — a near-term catalyst cited by retail/investors and referenced in reports that helped lift shares intraday. Esperion shares rise 8% after revenue tops forecasts and acquisition announced
• Positive Sentiment: Analyst support: HC Wainwright reiterated a Buy and issued a Q4 2026 EPS forecast (J. Pantginis) that implies analyst confidence in upcoming quarters, which can support the stock. (Research note dated March 10.)
• Neutral Sentiment: Investor materials available — earnings call transcript and slide deck published; useful for assessing management commentary on growth drivers and pipeline but not immediately price-moving by themselves. Esperion Therapeutics, Inc. (ESPR) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Short-interest reporting appears erroneous (entries show 0 shares / NaN changes and 0.0 days-to-cover) — currently not signaling material short squeeze or heavy short pressure.
• Negative Sentiment: Mixed headline/earnings math: some outlets flagged that EPS ($0.22) missed a specific Zacks consensus ($0.23) even though other consensus figures were lower; media framed the quarter as “mixed,” prompting some selling pressure. Esperion Therapeutics (ESPR) Misses Q4 Earnings Estimates ESPR stock falls after Esperion’s mixed Q4

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.